Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

At evaluere effekten af rygning på PK efter en enkeltdosis oral administration af GS1-144 tabletter.

15. september 2026 opdateret af: Changchun GeneScience Pharmaceutical Co., Ltd.

Et lægemiddel-lægemiddel-interaktionsstudie til evaluering af effekten af rygning (CYP1A2-inducer) på farmakokinetikken efter en enkelt oral dosis af GS1-144-tabletter hos kinesiske raske postmenopausale kvindelige forsøgspersoner

A Drug-Drug Interaction Study to Evaluate the Effect of Smoking (CYP1A2 Inducer) on the Pharmacokinetics Following a Single Oral Dose of GS1-144 Tablets in Chinese Healthy Postmenopausal Female Trial Participants

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This drug-drug interaction study adopts an open-label, parallel design to evaluate the effect of smoking on the PK following a single oral dose of GS1-144 tablets in Chinese healthy postmenopausal female trial participants.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

24

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Jinan
      • Shandong, Jinan, Kina, 100021
        • The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital)

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

40 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Kvinde

Beskrivelse

Inclusion Criteria:

1)40 to 65 years of age (inclusive) at the time of signing the informed consent form (ICF).

2)Trial participants are healthy females who meet any of the following criteria during screening:

  1. Consecutive spontaneous amenorrhea ≥ 12 months.

  2. Consecutive spontaneous amenorrhea ≥ 6 months but < 12 months, with serum follicle-stimulating hormone (FSH) levels > 40 IU/L.

  3. ≥ 6 weeks after bilateral oophorectomy.

  4. History of hysterectomy with preservation of one or both ovaries and FSH levels > 40 IU/L.

    3)Body weight ≥ 45 kg, and body mass index (BMI) within the range of 18-28 kg/m2 (inclusive).

    4)Able to communicate well with the investigator, understand and comply with all study requirements, voluntarily agree to participate in the trial, and understand and voluntarily sign the ICF.

    5)Smoker:smoking ≥ 10 cigarettes per day within 6 months prior to screening, and urinary cotinine level ≥ 1,000 ng/mL at screening. Smokers will be required to continue smoking in designated areas according to their habits during the study.

    6)Non-smoker: no smoking within 6 months prior to screening, and urinary cotinine level < 200 ng/mL at screening.

    Exclusion Criteria:

    1. Known history of hypersensitivity to the investigational drug, any of its excipients, or related formulations; or a history of allergic disorders (including but not limited to asthma, urticaria); or being allergy-prone (e.g., known allergy to two or more substances).
    2. History or current diagnosis of diseases of the circulatory, digestive, urinary, respiratory, endocrine and metabolic, hematological and lymphatic, immune, psychiatric and neurological, or dermatological systems, and deemed unsuitable for participation by the investigator.
    3. History of severe infection, serious trauma, or major surgery within 6 months prior to screening, or planning to undergo surgery during the trial.
    4. Blood donation or blood loss ≥ 400 mL, or receipt of blood transfusion within 3 months prior to screening, or planning to donate blood within 1 month after the end of the trial.
    5. Use of any prescription medications [including but not limited to drugs known to alter hepatic enzyme activity (e.g., glucocorticoids, sex hormones, anticonvulsants, cyclosporine)] within 4 weeks prior to screening, or use of any over-the-counter (OTC) medications (including but not limited to herbal medicines, herbal compound prescriptions, health supplements) or vitamin supplements within 2 weeks prior to screening.
    6. Trial participants with abnormal findings in physical examination, chest X-ray, abdominal and urinary ultrasound, genital ultrasound, thyroid and parathyroid ultrasound, or laboratory tests at screening, which are deemed unsuitable for participation by the investigator.
    7. During screening or on D-1, any of the following liver function test results as follows: alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥ 1.5 × upper limit of normal (ULN), or total bilirubin (TBIL) ≥ 1.2 × ULN.
    8. Abnormal vital signs and deemed unsuitable for participation by the investigator, or systolic blood pressure ≥ 150 mmHg and/or diastolic blood pressure ≥ 100 mmHg during screening.
    9. Abnormal 12-lead ECG findings and deemed unsuitable for participation by the investigator, or QTcF > 470 ms (Fridericia's formula: QTcF = QT/RR0.33, RR = 60/heart rate) during screening.
    10. Positive test results for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or Treponema pallidum antibody (TP-Ab) during screening.
    11. Participation in another clinical trial within 3 months prior to screening (except for trial participants who did not receive any investigational intervention), or current participation in any other clinical trial.
    12. Current or past history of drug abuse within 1 year, or positive urine multi-drug test panel.
    13. Positive alcohol breath test or history of excessive alcohol consumption (defined as >14 units of alcohol per week) within 3 months prior to screening (One standard alcohol unit is equivalent to 17.5 mL or 14 g of pure ethanol. Alcohol content is labeled by volume (ABV) for all beverage types. This corresponds approximately to 35 mL of 50% spirits or 350 mL of 5% beer), or unwillingness to abstain from alcohol or any alcohol-containing products during the trial.
    14. Consumption of food or beverages that may affect drug metabolism (e.g., containing grapefruit, starfruit, or their products) within 48 hours prior to admission.
    15. Excessive consumption of tea, coffee, or caffeinated beverages (>8 cups per day, 1 cup=250 mL) within 3 months prior to screening; or consumption of any food or beverage containing or metabolized to caffeine or xanthine (e.g., coffee, tea, chocolate, cola) within 24 hours prior to admission.
    16. Pregnant or lactating women, or those who have a clinically significant positive pregnancy test result.
    17. Poor venous access, a history of difficult venipuncture, intolerance to venipuncture/intravenous indwelling needle, or needle/blood phobia.
    18. Other conditions deemed unsuitable by the investigator.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: GS1-144 tabletter

All trial participants will receive the investigational drug (GS1-144 tablets) at a dose of 30 mg.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Primære PK-parametre for GS1-144: Cmax.
Tidsramme: op til 72 timer
op til 72 timer
Primære PK-parametre for GS1-144: AUC0-t.
Tidsramme: op til 72 timer
op til 72 timer
Primære PK-parametre for GS1-144: AUC0-∞.
Tidsramme: op til 72 timer
op til 72 timer
Sekundære PK-parametre for GS1-144: Tmax.
Tidsramme: op til 72 timer
op til 72 timer
Sekundære PK-parametre for GS1-144: eliminationshastighedskonstant (λz).
Tidsramme: op til 72 timer
op til 72 timer
Sekundære PK-parametre for GS1-144: t1/2.
Tidsramme: op til 72 timer
op til 72 timer
Sekundære PK-parametre for GS1-144:CL/F.
Tidsramme: op til 72 timer
op til 72 timer
Sekundære PK-parametre for GS1-144: Vd/F.
Tidsramme: op til 72 timer
op til 72 timer
Sekundære PK-parametre for GS1-144: AUC_%Extrap.
Tidsramme: op til 72 timer
op til 72 timer

Sekundære resultatmål

Resultatmål
Tidsramme
PK-parametre for den primære metabolitt M1: Cmax.
Tidsramme: op til 72 timer
op til 72 timer
PK-parametre for den primære metabolit M1: AUC0-t.
Tidsramme: op til 72 timer
op til 72 timer
PK-parametre for den primære metabolit M1: AUC0-∞.
Tidsramme: op til 72 timer
op til 72 timer
PK-parametre for primærmetabolitten M1: Tmax.
Tidsramme: op til 72 timer
op til 72 timer
PK-parametre for den primære metabolit M1: λz.
Tidsramme: op til 72 timer
op til 72 timer
PK-parametre for den primære metabolit M1: t1/2.
Tidsramme: op til 72 timer
op til 72 timer
PK-parametre for primær metabolitten M1: AUC_%Extrap.
Tidsramme: op til 72 timer
op til 72 timer
Bivirkninger (BEs).
Tidsramme: op til 72 timer
op til 72 timer

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

20. maj 2026

Primær færdiggørelse (Faktiske)

2. juli 2026

Studieafslutning (Faktiske)

29. juli 2026

Datoer for studieregistrering

Først indsendt

25. marts 2026

Først indsendt, der opfyldte QC-kriterier

15. april 2026

Først opslået (Faktiske)

16. april 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

15. september 2026

Sidst verificeret

1. marts 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • GenSci074-107

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .